These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Molecular markers and determinants of prostate cancer metastasis. Gopalkrishnan RV; Kang DC; Fisher PB J Cell Physiol; 2001 Dec; 189(3):245-56. PubMed ID: 11748582 [TBL] [Abstract][Full Text] [Related]
6. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Bickers B; Aukim-Hastie C Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347 [TBL] [Abstract][Full Text] [Related]
7. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095 [TBL] [Abstract][Full Text] [Related]
8. The role of tissue microarrays in prostate cancer biomarker discovery. Datta MW; True LD; Nelson PS; Amin MB Adv Anat Pathol; 2007 Nov; 14(6):408-18. PubMed ID: 18049130 [TBL] [Abstract][Full Text] [Related]
9. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995 [TBL] [Abstract][Full Text] [Related]
10. Blood biomarkers for prostate cancer detection and prognosis. Shariat SF; Karam JA; Roehrborn CG Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720 [TBL] [Abstract][Full Text] [Related]
11. [Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis]. Ohori M Gan To Kagaku Ryoho; 2009 Jan; 36(1):6-10. PubMed ID: 19151558 [TBL] [Abstract][Full Text] [Related]
12. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Yu J; Yu J; Rhodes DR; Tomlins SA; Cao X; Chen G; Mehra R; Wang X; Ghosh D; Shah RB; Varambally S; Pienta KJ; Chinnaiyan AM Cancer Res; 2007 Nov; 67(22):10657-63. PubMed ID: 18006806 [TBL] [Abstract][Full Text] [Related]
14. Clinical cancer proteomics: promises and pitfalls. Alaiya A; Al-Mohanna M; Linder S J Proteome Res; 2005; 4(4):1213-22. PubMed ID: 16083271 [TBL] [Abstract][Full Text] [Related]
15. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective. Matharoo-Ball B; Ball G; Rees R Vaccine; 2007 Sep; 25 Suppl 2():B110-21. PubMed ID: 17916461 [TBL] [Abstract][Full Text] [Related]
16. Disease mechanism and biomarkers of oral squamous cell carcinoma. Brinkman BM; Wong DT Curr Opin Oncol; 2006 May; 18(3):228-33. PubMed ID: 16552233 [TBL] [Abstract][Full Text] [Related]
17. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Mucci LA; Pawitan Y; Demichelis F; Fall K; Stark JR; Adami HO; Andersson SO; Andrén O; Eisenstein AS; Holmberg L; Huang W; Kantoff PW; Perner S; Stampfer MJ; Johansson JE; Rubin MA Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):249-51. PubMed ID: 18199732 [TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. Sardana G; Jung K; Stephan C; Diamandis EP J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523 [TBL] [Abstract][Full Text] [Related]